---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062192"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:59:17.730464+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared

## Summary
- Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.
- Twelve-month sales ended June 30, 2025 were $28.3M, up 22% YoY from $23.2M.
- Order backlog reduced to under $100k as of June 30, 2025, down from $3.4M on May 6.
- Evaluating additional capacity investments to increase production capacity to ~$40M per year.
- Conference call scheduled for August 15, 2025 to discuss full Q2 2025 financial results.

## SEC filing metadata
- accession: 0001213900-25-062192
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/0001213900-25-062192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/ea0248347-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062192
- JSON: https://secwatch.observer/filing/0001213900-25-062192.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.